Taysha Gene Therapies, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $37.4M | $50.7M | $96.6M |
| Jun 2022 | $37.6M | $32.5M | $66.2M |
| Sep 2022 | $37.8M | $10.7M | $34.3M |
| Dec 2022 | $38.0M | $949.0K | $87.9M |
| Mar 2023 | $38.2M | $-14.9M | $63.4M |
| Jun 2023 | $38.4M | $-37.1M | $45.1M |
| Sep 2023 | $38.5M | $-49.1M | $164.3M |
| Dec 2023 | $40.5M | $74.9M | $143.9M |
| Mar 2024 | $40.5M | $53.8M | $124.0M |
| Jun 2024 | $37.8M | $108.9M | $172.7M |
| Sep 2024 | $43.0M | $88.8M | $157.7M |
| Dec 2024 | $43.9M | $71.5M | $139.0M |
| Mar 2025 | $42.5M | $55.1M | $116.6M |
| Jun 2025 | $41.1M | $248.7M | $312.8M |
| Sep 2025 | $50.9M | $219.0M | $297.3M |
| Dec 2025 | $50.1M | $246.9M | $319.8M |
| Mar 2026 | $49.0M | $211.9M | $276.6M |
| Jun 2026 | $49.3M | $387.3M | $455.4M |